Compare Merck & Co., Inc. (MRK) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NetApp Inc. — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while NetApp Inc. trades at $167.96 (market cap $31.57B). The key difference: Merck & Co., Inc. is far larger — about 9.7× NetApp Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | NTAP | |
|---|---|---|
Market Cap | $307.25B | $31.57B |
Sector | Health | Technology |
52-Week High | $129.52 | $181.08 |
52-Week Low | $77.60 | $94.11 |
Enterprise Value | $350.66B | $30.72B |
Dividend Yield | 2.73% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
NTAP trades at $165.70, up 1.11% today, near its consensus price target of $167.45. The stock shows strong fundamentals with a net income margin of 18.43% and consistent earnings beats in recent quarters. Recent acquisition of DataPelago aims to bolster AI infrastructure capabilities, while technical indicators signal a neutral near-term trend with support at $160 and resistance at $166.
Outlook remains positive driven by AI and cloud demand, though high valuation ratios like P/E of 25.38 and debt-to-asset ratio of 29.89 pose risks. Analysts are mixed with 36.6% buy ratings, suggesting cautious optimism for growth trajectory amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
